Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2022-502951-77-00
CTIS2022-502951-77-00
Active, not recruiting
Phase 1

A study to evaluate the effect of multiple doses of carbamazepine on how long aticaprant (JNJ-67953964) stays in the body (pharmacokinetics) in healthy adults

Janssen - Cilag International0 sites20 target enrollmentFebruary 3, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy Adult ParticipantsTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy Adult Participants
Sponsor
Janssen - Cilag International
Enrollment
20
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 3, 2023
End Date
September 11, 2023
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study to evaluate the effect of multiple doses of carbamazepine and itraconazole on how long JNJ-55308942 stays in the body (pharmacokinetics) in healthy adults.Bipolar depressionTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
CTIS2023-504055-27-00Janssen - Cilag International48
Completed
Phase 4
A study to evaluate the effect of two doses of oral melatonin on anxiety and pain relief in patients undergoing lower limb surgeries.
CTRI/2020/02/023330Department of Anaesthesiology and Critical care63
Completed
Phase 1
A study in healthy subjects to see the effects of the test medicine on the body when given in fed or fasted state as a multiple doseTransthyretin (TTR) Amyloidosis (ATTR)Digestive System
ISRCTN11628974Eidos Therapeutics, Inc.28
Recruiting
Phase 1
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease (I8G-MC-LMDD)Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
JPRN-jRCT2080223501Eli Lilly Japan K.K.
Completed
Phase 3
icorice gargling to decrease sore throat after surgeryCondition 1: Postoperative Sore Throat (POST). Condition 2: Postextubation Cough.Pain in throatCough
IRCT201411115362N21Isfahan University of Medical Sciences144